Show simple item record

dc.contributor.authorHaworth, Catherine
dc.contributor.authorStevens, R
dc.contributor.authorTesta, Nydia G
dc.date.accessioned2010-12-03T10:56:52Z
dc.date.available2010-12-03T10:56:52Z
dc.date.issued1985-01
dc.identifier.citationSerial incidence of bone marrow GM-CFC prior to the development of acute non-lymphoblastic leukaemia in a child treated for non-Hodgkin's lymphoma. 1985, 59 (1):79-84 Br J Haematolen
dc.identifier.issn0007-1048
dc.identifier.pmid3970853
dc.identifier.doi10.1111/j.1365-2141.1985.tb02966.x
dc.identifier.urihttp://hdl.handle.net/10541/117076
dc.description.abstractA child treated for NHL developed acute non-lymphoblastic leukaemia 27 months after stopping treatment. Serial in vitro bone marrow studies showed a normal incidence of GM-CFC following treatment. However, GM-CFC incidence dropped at least 15 months prior to the development of leukaemia. This was associated with an asymptomatic neutropenia but no disturbance of bone marrow morphology. It is concluded that sub-clinical disturbances of bone marrow function may play an important part in leukaemogenesis.
dc.language.isoenen
dc.subjectHaematopoietic Stem Cellsen
dc.subjectLeukaemiaen
dc.subjectPrimary Multiple Canceren
dc.subject.meshAcute Disease
dc.subject.meshBone Marrow
dc.subject.meshChild
dc.subject.meshHematopoietic Stem Cells
dc.subject.meshHumans
dc.subject.meshLeukemia
dc.subject.meshLeukocyte Count
dc.subject.meshLymphoma
dc.subject.meshMale
dc.subject.meshNeoplasms, Multiple Primary
dc.subject.meshNeutropenia
dc.subject.meshNeutrophils
dc.titleSerial incidence of bone marrow GM-CFC prior to the development of acute non-lymphoblastic leukaemia in a child treated for non-Hodgkin's lymphoma.en
dc.typeArticleen
dc.contributor.departmentPaterson Laboratories, Christie Hospital, Manchester, UKen
dc.identifier.journalBritish Journal of Haematologyen
html.description.abstractA child treated for NHL developed acute non-lymphoblastic leukaemia 27 months after stopping treatment. Serial in vitro bone marrow studies showed a normal incidence of GM-CFC following treatment. However, GM-CFC incidence dropped at least 15 months prior to the development of leukaemia. This was associated with an asymptomatic neutropenia but no disturbance of bone marrow morphology. It is concluded that sub-clinical disturbances of bone marrow function may play an important part in leukaemogenesis.


This item appears in the following Collection(s)

Show simple item record